Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli

Nucleotide sequence analysis of the gyrA genes of 10 spontaneous quinolone-resistant gyrA mutants of Escherichia coli KL16, including four mutants examined previously, disclosed that quinolone resistance was caused by a point mutation within the region between amino acids 67 and 106, especially in the vicinity of amino acid 83, of the GyrA protein.

[1]  A. Wyke,et al.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones , 1989, Antimicrobial Agents and Chemotherapy.

[2]  D. Holmes,et al.  A rapid boiling method for the preparation of bacterial plasmids. , 1981, Analytical biochemistry.

[3]  Jeffrey H. Miller.  Experiments in molecular genetics , 1972 .

[4]  J. Matsumoto,et al.  Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives. , 1975, Journal of medicinal chemistry.

[5]  S. Inoue,et al.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity , 1981, Journal of bacteriology.

[6]  S. Nakamura,et al.  gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.

[7]  J. Wang,et al.  Mapping the active site tyrosine of Escherichia coli DNA gyrase. , 1987, The Journal of biological chemistry.

[8]  D. Kaminsky,et al.  Quinolone antibacterial agents. Oxolinic acid and related compounds. , 1968, Journal of medicinal chemistry.

[9]  Mika Nakamura.  gyrAandgyrBMutations inQuinolone-Resistant Strains ofEscherichia coli , 1989 .

[10]  A. Wyke,et al.  Cloning andCharacterization ofaDNA Gyrase A Genefrom Escherichia coli ThatConfers Clinical Resistance to4-Quinolones , 1989 .

[11]  M. Gellert,et al.  DNA gyrase: subunit structure and ATPase activity of the purified enzyme. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Kvam,et al.  Bioevaluation of the Antibacterial Flumequine for Urinary Tract Use , 1976, Antimicrobial Agents and Chemotherapy.

[13]  W. Kohlbrenner,et al.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. , 1989, The Journal of biological chemistry.

[14]  W. Boll,et al.  Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1. , 1979, Nucleic acids research.

[15]  K. R. Woods,et al.  Prediction of protein antigenic determinants from amino acid sequences. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Y. Chou,et al.  Prediction of the secondary structure of proteins from their amino acid sequence. , 2006 .

[17]  S. Inoue,et al.  Mode of Incomplete Cross-Resistance Among Pipemidic, Piromidic, and Nalidixic Acids , 1978, Antimicrobial Agents and Chemotherapy.

[18]  J. Messing.  [2] New M13 vectors for cloning , 1983 .

[19]  J. Matsumoto,et al.  Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. , 1990, Journal of medicinal chemistry.

[20]  M. Gellert,et al.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents. , 1986, Journal of medicinal chemistry.

[22]  G. Y. Lesher,et al.  1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. , 1962, Journal of medicinal and pharmaceutical chemistry.

[23]  J. Messing.  New M13 vectors for cloning. , 1983, Methods in enzymology.

[24]  K. Mizuuchi,et al.  Nalidixic acidresistance: Asecond genetic character involved inDNA gyrase activity , 1977 .